Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

August 2012

Clinical Trials, Cohort Studies, Pilot Studies

Patients' Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection. Kauf TL, Mohamed AF, Hauber AB, Fetzer D, Ahmad A. Patient. 2012 Jul 10. doi: 10.2165/11633580-000000000-00000. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22775534

Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study. Lee MH, Yang HI, Lu SN, et al. J Infect Dis. 2012 Aug;206(4):469-477. Epub 2012 Jul 17.

http://www.ncbi.nlm.nih.gov/pubmed/22811301

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial. Meyer SD, Dierynck I, Ghys A, et al. Hepatology. 2012 Jul 16. doi: 10.1002/hep.25962. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22806681

Escitalopram for the Prevention of Peginterferon-α2a-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease: A Randomized Trial.

Schaefer M, Sarkar R, Knop V, et al. Ann Intern Med. 2012 Jul 17;157(2):94-103.

http://www.ncbi.nlm.nih.gov/pubmed/22801672

IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. Karchava M, Sharvadze L, Chkhartishvili N, et al. Eur J Gastroenterol Hepatol. 2012 Jul;24(7):817-23.

http://www.ncbi.nlm.nih.gov/pubmed/22569080

The effect of increased oxidative stress and ferritin in reducing the effectiveness of therapy in chronic hepatitis C patients. Chiou YL, Chen YH, Ke T, Ko WS. Clin Biochem. 2012 Jul 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22760008

Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. Brennan BJ, Xu ZX, Grippo J. Br J Clin Pharmacol. 2012 Jul 6. doi: 10.1111/j.1365-2125.2012.04373.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22765278

Bipolar patients can safely and successfully receive interferon-based hepatitis C antiviral treatment. Kelly EM, Corace K, Emery J, Cooper CL. Eur J Gastroenterol Hepatol. 2012 Jul;24(7):811-6.

http://www.ncbi.nlm.nih.gov/pubmed/22495398

Fatigue Before, During and After Antiviral Therapy of Chronic Hepatitis C: Results from the Virahep-C Study. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. J Hepatol. 2012 Jul 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22760009

Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients. Rodríguez-Torres M, Burguera J, Hallman D, Rodríguez-Orengo J, Echeandia M. Ann Hepatol. 2012 Jul;11(4):450-63.

http://www.ncbi.nlm.nih.gov/pubmed/22700626

Basic and Applied Science, Pre-Clinical Studies

Hepatitis C virus nonstructural 5B protein interacts with cyclin A2 and regulates viral propagation. Pham LV, Ngo HT, Lim YS, Hwang SB. J Hepatol. 2012 Jul 12. [Epub ahead of print]

http://ww.ncbi.nlm.nih.gov/pubmed/22796893

The CXCR3(+)CD56Bright Phenotype Characterizes a Distinct NK Cell Subset with Anti-Fibrotic Potential That Shows Dys-Regulated Activity in Hepatitis C. Eisenhardt M, Glässner A, Krämer B, et al. PLoS One. 2012;7(7):e38846. Epub 2012 Jul 5.

http://www.ncbi.nlm.nih.gov/pubmed/22792160

Correlation Between NS5A Dimerization and HCV replication. Lim PJ, Chatterji U, Cordek D, et al. J Biol Chem. 2012 Jul 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22801423

Chemokine CXCL10 at Week 4 of Treatment Predicts Sustained Virological Response in Patients with Chronic Hepatitis C. Kurelac I, Lepej SZ, Grlgic I, et al. J Interferon Cytokine Res. 2012 Jul 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22799464

Hepatitis C virus-specific T cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis. Li S, Vriend LE, Nasser IA, Popov Y, et al. Hepatology. 2012 Jul 14. doi: 10.1002/hep.25951. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22806830

A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms. Krishnan SM, Dixit NM. Antivir Ther. 2012 Jul 18. doi: 10.3851/IMP2251. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22809728

Levels and values of circulating endothelial progenitor cells, soluble angiogenic factors, and mononuclear cell apoptosis in liver cirrhosis patients.

Chen CH, Chang LT, Tung WC, et al. J Biomed Sci. 2012 Jul 18;19(1):66. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22809449

Novel Cell Culture-Adapted Genotype 2a Hepatitis C Virus Infectious Clone. Date T, Kato T, Kato J, et al. J Virol. 2012 Jul 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22787209

Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses. Zhu J, Li Y, Yu H, Zhang L, Mao X, Hou T. Comb Chem High Throughput Screen. 2012 Jul;15(6):439-50.

http://www.ncbi.nlm.nih.gov/pubmed/22263860

CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by JNK activation independent from the interferon pathway. Rau SJ, Hildt E, Himmelsbach K, et al. Hepatology. 2012 Jul 19. doi: 10.1002/hep.25966. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22814930

Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinemia are associated with circulating levels of IFN-γ and TNF-α. Antonelli A, Fallahi P, Ferrari SM, et al. Clin Exp Rheumatol. 2012 Jul 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22766105

Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study. Reddy MB, Chen Y, Haznedar JO, Fretland J, Blotner S, Smith P, Tran JQ. Clin Pharmacokinet. 2012 Jul 1;51(7):457-65. doi: 10.2165/11599700-000000000-00000.

http://www.ncbi.nlm.nih.gov/pubmed/22624502

HIV/HCV Coinfection

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. Martinez V, Ta TD, Mokhtari Z, et al. BMC Res Notes. 2012 Jul 9;5:180.

http://www.ncbi.nlm.nih.gov/pubmed/22490728

Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals. Clausen LN, Astvad K, Ladelund S, Larsen MV, Schønning K, Benfield T. AIDS. 2012 Jul 31;26(12):1509-16.

http://www.ncbi.nlm.nih.gov/pubmed/22555162

Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. Limketkai BN, Mehta SH, Sutcliffe CG, et al. JAMA. 2012 Jul 25;308(4):370-8.

http://www.ncbi.nlm.nih.gov/pubmed/22820790

HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV coinfection. Audsley J, du Cros P, Goodman Z, et al. J Med Virol. 2012 Jul;84(7):993-1001. doi: 10.1002/jmv.23236.

http://www.ncbi.nlm.nih.gov/pubmed/22585714

HCV co-infection possibly promotes left ventricular dysfunction development: analysis of brain natriuretic peptide serum levels in HCV/HIV-coinfected and HIV-monoinfected patients. Dabrowska MM, Mikula T, Wiercinska-Drapalo A. Eur J Gastroenterol Hepatol. 2012 Jul 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22825646

HIV Co-infection With Hepatitis C Virus: Evolving Epidemiology and Treatment Paradigms. Taylor LE, Swan T, Mayer KH. Clin Infect Dis. 2012 Jul;55 Suppl 1:S33-42.

http://www.ncbi.nlm.nih.gov/pubmed/22715212

Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. Petta S, Macaluso FS, Cammà C, Marco VD, Cabibi D, Craxì A. Liver Int. 2012 Jul 5. doi: 10.1111/j.1478-3231.2012.02842.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22764879

Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults.

Tsui JI, Cheng DM, Libman H, Bridden C, Samet J. AIDS Care. 2012 Jul;24(7):820-7. Epub 2012 Jan 24.

http://www.ncbi.nlm.nih.gov/pubmed/22272656

Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). Wegzyn CM, Wyles DL. Curr Opin Pharmacol. 2012 Jul 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22770811

Acute HCV/HIV Co-infection Is Associated with Cognitive Dysfunction and Cerebral Metabolite Disturbance, but Not Increased Microglial Cell Activation.

Garvey LJ, Pavese N, Ramlackhansingh A, et al. PLoS One. 2012;7(7):e38980. Epub 2012 Jul 12.

http://www.ncbi.nlm.nih.gov/pubmed/22808022

Complementary and Alternative Medicine

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. Fried MW, Navarro VJ, Afdhal N, et al. JAMA. 2012 Jul 18;308(3):274-82.

http://www.ncbi.nlm.nih.gov/pubmed/22797645

Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Rocco A, Compare D, Coccoli P, et al. Gut. 2012 Jul 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22810757

Epidemiology, Diagnostics, and Miscellaneous Works

A 25-Year Study of the Clinical and Histologic Outcomes of Hepatitis C Virus Infection and Its Modes of Transmission in a Cohort of Initially Asymptomatic Blood Donors.

Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, e al. J Infect Dis. 2012 Jul 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22740714

Performance of Real-Time Strain Elastography, Transient Elastography, and Aspartate-to-Platelet Ratio Index in the Assessment of Fibrosis in Chronic Hepatitis C. Ferraioli G, Tinelli C, Malfitano A, et al. AJR Am J Roentgenol. 2012 Jul;199(1):19-25.

http://www.ncbi.nlm.nih.gov/pubmed/22733889

Pegylated interferon for chronic hepatitis C in children affects growth and body composition: Results from the pediatric study of hepatitis C (PEDS-C) trial. Jonas MM, Balistreri W, Gonzalez-Peralta RP, Haber B, Lobritto S, ET AL. Hepatology. 2012 Aug;56(2):523-31. doi: 10.1002/hep.25690. Epub 2012 Jul 6.

http://www.ncbi.nlm.nih.gov/pubmed/22383118

Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles. Gelberg L, Robertson MJ, Arangua L, et al. Public Health Rep. 2012 Jul;127(4):407-21.

http://www.ncbi.nlm.nih.gov/pubmed/22753984

Global burden of hepatitis C: considerations for healthcare providers in the United States.

Averhoff FM, Glass N, Holtzman D. Clin Infect Dis. 2012 Jul;55 Suppl 1:S10-5.

http://www.ncbi.nlm.nih.gov/pubmed/22715208

Expected and Actual Case Ascertainment and Treatment Rates for Children Infected with Hepatitis C in Florida and the United States: Epidemiologic Evidence from Statewide and Nationwide Surveys. Delgado-Borrego A, Smith L, Jonas MM, et al. J Pediatr. 2012 Jul 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22765955

Prevalence of Hepatitis C Virus Infection in the Veteran Population Undergoing Total Joint Arthroplasty. Calore BL, Cheung RC, Giori NJ. J Arthroplasty. 2012 Jul 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22770853

HCV Infection Prevalence Lower Than Expected among 18-40-Year-Old Injection Drug Users in San Diego, CA. Garfein RS, Rondinelli A, Barnes RF, et al. J Urban Health. 2012 Jul 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22766605

Challenging stereotypes and changing attitudes: Improving quality of care for people with hepatitis C through Positive Speakers programs. Brener L, Wilson H, Rose G, Mackenzie A,

http://www.ncbi.nlm.nih.gov/pubmed/22783938

Perceived Barriers to Hepatitis C Therapy for Patients Receiving Opioid Agonist Treatment. Zickmund SL, Campbell SA, Tirado CF, Zook CL, Weinrieb RM. J Addict Med. 2012 Jul 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22790464

Liver Cancer

Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients. Hikita H, Nakagawa H, Tateishi R, et al. J Gastroenterol. 2012 Jul 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22790352

Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Khattab MA, Eslam M, Mousa YI, et al. Ann Hepatol. 2012 Jul;11(4):487-94.

http://www.ncbi.nlm.nih.gov/pubmed/22700630

The role of chemokine CC ligand 20 in patients with liver cirrhosis and hepatocellular carcinoma. Soliman HH, Nagy H, Kotb N, Alm El-Din MA. Int J Biol Markers. 2012 Jul 19;27(2):e125-31. doi: 10.5301/JBM.2012.9097.

http://www.ncbi.nlm.nih.gov/pubmed/22388957

A Comparative Analysis of Hepatocellular Carcinoma after Hepatic Resection in Young versus Elderly Patients. Lee CR, Lim JH, Kim SH, et al. J Gastrointest Surg. 2012 Jul 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22810298

Cancer-associated carbohydrate antigens as potential biomarkers for hepatocellular carcinoma. Wu CS, Yen CJ, Chou RH, et al. PLoS One. 2012;7(7):e39466. Epub 2012 Jul 13.

http://www.ncbi.nlm.nih.gov/pubmed/22808038